angiotensin-i-converting enzyme (ace) inhibitors from marine resources prospects in the pharmaceutical industry从海洋资源angiotensin-i-converting酶(ace)抑制剂在制药行业的前景.pdfVIP

Mar. Drugs 2010, 8, 1080-1093; doi:10.3390/md8041080 OPEN ACCESS Marine Drugs ISSN 1660-3397 /journal/marinedrugs Review Angiotensin-I-Converting Enzyme (ACE) Inhibitors from Marine Resources: Prospects in the Pharmaceutical Industry Isuru Wijesekara 1 and Se-Kwon Kim 1,2,* 1 Marine Biochemistry Laboratory, Department of Chemistry, Pukyong National University, Busan 608-737, Korea; E-Mail: isurumatara@ (I.W.) 2 Marine Bioprocess Research Center, Pukyong National University, Busan 608-737, Korea * Author to whom correspondence should be addressed; E-Mail: sknkim@pknu.ac.kr; Tel.: +82-51-629-7094; Fax: +82-51-629-7099. Received: 19 February 2010, in revised form: 8 March 2010 / Accepted: 29 March 2010 / Published: 31 March 2010 Abstract: Hypertension or high blood pressure is one of the major independent risk factors for cardiovascular diseases. Angiotensin-I-converting enzyme (EC ; ACE) plays an important physiological role in regulation of blood pressure by converting angiotensin I to angiotensin II, a potent vasoconstrictor. Therefore, the inhibition of ACE activity is a major target in the prevention of hypertension. Recently, the search for natural ACE inhibitors as alternatives to synthetic drugs is of great interest to prevent several side effects and a number of novel compounds such as bioactive peptides, chitooligosaccharide derivatives (COS) and phlorotannins have been derived from marine organisms as potential ACE inhibitors. These inhibitory